Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yonsei University
Age
20–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged between 20 and 85 years at visit 1
Patients with ankle-brachial index (ABI) of less than 0.9 in one or both legs with history of intermittent claudication stable for the previous 6 months
Patients whose statins, anti hypertensive medications and antiplatelet medications are stable for the past 6 months. Statins and cilostazol are allowed but needs to be stable for the past 6 months (diabetic medications may be changed)
Patients whose blood pressure is more than 140/90 mmHg with/without anti-hypertension treatment
You may not be if
Blood pressure of more than 180/110 mmHg
Patients taking ARBs or ACE inhibitors treatment for at least 6 months before
Patients taking aldosterone receptor antagonists at least 6 months before
Patients with serum creatinine of more than 3 mg/dL
serum potassium (K+) \> 5.5mg/dl
History of bilateral renal artery stenosis
History of acute coronary syndrome or heart failure hospitalization within 6 months
Peripheral arterial revascularization planned within 1 month
Critical limb ischemia
Patients with impaired cognition (e.g. dementia)
pregnancy or women at age of childbearing potential
Clareo Health | Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)
